Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a conceptual combination of three intravenous iron replacement products—ferric carboxymaltose, ferric derisomaltose, and ferumoxytol—all used to treat iron deficiency and iron deficiency anemia when oral iron is ineffective or not tolerated, or in settings such as chronic kidney disease and other causes of significant iron deficiency.[4][5][2][3][8][6] Each component is a colloidal iron–carbohydrate complex that delivers bioavailable ferric iron to the reticuloendothelial system, from which iron is released and incorporated into hemoglobin and other iron-dependent proteins, thereby correcting anemia; ferric carboxymaltose and ferric derisomaltose allow administration of large single doses over short infusions, while ferumoxytol is a superparamagnetic iron oxide complex that has also been used as an MRI contrast agent.[1][4][5][3][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferric carboxymaltose + ferric derisomaltose + ferumoxytol.